期刊文献+

膜攻击复合物C5b-9的研究现状 被引量:4

原文传递
导出
摘要 C5b-9也称膜攻击复合物,是补体系统经经典、旁路和凝集素三条途径激活后形成的共同末端效应产物。近年来,国内外许多研究发现沉积于细胞表面的C5b-9能刺激多种细胞的多种生物学活性改变,包括产生炎性介质、细胞因子,并诱导膜蛋白表达等,C5b-9的这种细胞刺激效应在多种疾病的发病机制和病程进展中发挥作用,尤其是亚溶解型C5b-9,在炎症、神经系统疾病、肾脏病和动脉粥样硬化等疾病中具有致病等多重作用。
作者 丛璐 蒲传强
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第1期67-70,共4页 National Medical Journal of China
  • 相关文献

参考文献27

  • 1王金泉.膜攻击复合物与肾脏疾病[J].国外医学(泌尿系统分册),1996,16(5):228-232. 被引量:1
  • 2Cybulsky AV,Takano T,Papillon J,et al. Activation of the extracel-lular signal-regulated kinase by complement C5b-9.Am J Physiol Renal Physiol,2005,289:F593-603.
  • 3吴佩泽,华树成,杨雪梅.补体攻膜复合物C5b-9处理后的树突状细胞对同种异体淋巴细胞的作用[J].吉林大学学报(医学版),2008,34(1):78-81. 被引量:2
  • 4Panesar M,Papillon J,MaTavish AJ,et al.J Immunol,1997,159:3584-3594.
  • 5Cybulsky AV,Papillon J,McTavish A J,et al. Complementinduced phospholipase A2 activation in experimental membranous nephropathy.Kidney lnt,2000,57:1052-1062.
  • 6蔡文莉,黄颂敏.C5b-9复合物与肾脏疾病研究进展[J].国外医学(泌尿系统分册),2003,23(5):568-571. 被引量:4
  • 7Neale TJ, Ojha P, Exner M,et al. Proteinuria in passive Heymannnephritis is associated with lipid peroxidation and formation of adducts on type Ⅳ collagen.J Clin Invest,1994,94:1577-1584.
  • 8Peng H,Takano T,Papillon J,et al.J Immonol,2002,169:2594-2601.
  • 9陈圳炜,唐德燊,刘华锋.Heymann肾炎发病机制的研究现状[J].广东医学院学报,2008,26(2):205-208. 被引量:5
  • 10Shankland SJ,Pippin J,Pichler RH,et al.Differential expression of transfprming growth factor-beta isoform and receptors in experimental membranous nephropathy.Kidney Int,1996,50:116-124.

二级参考文献144

共引文献23

同被引文献37

  • 1郑娜,杨天潼,梁曼,张海东,李立平,阿兰达,刘良.Characterization of Protein in Old Myocardial Infarction by FTIR Micro-spectroscopy[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2010,30(4):546-550. 被引量:3
  • 2邱明才,孟春梅.糖尿病并发症发病过程中的补体活化作用[J].中华内分泌代谢杂志,2006,22(3):303-305. 被引量:14
  • 3方莲花,杜冠华.晚期糖基化终产物和抗动脉粥样硬化药物发现策略[J].中国药学杂志,2007,42(11):801-804. 被引量:4
  • 4Hoogendijk JE, Amato AA, Lecky BR, et al. l l9th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands [ J]. Neuromuscul Disord, 2004,14 ( 5 ) : 337-345.
  • 5Kissel JT, Halterman RK, Rammohan KW, et al. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis[ J]. Arch Neurol, 1991, 48( 1 ) : 26-30.
  • 6Miller T, A1-Lozi MT, Lopate G, et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological tatures [J]. J Neurol Neurosurg Psychiatry, 2002, 73(4) : 420-428.
  • 7Gherardi RK. Pathogenic aspects of dernmtomyositis, polymyositis and overlap myositis[J]. Presse Med, 2011, 40(4 Pt 2) : 209- 218.
  • 8Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis[J]. Laneet, 2003, 362 ( 9388 ) :971-982.
  • 9Pavlath GK. Regulation of class MHC expression in skeletal musele: deleterious effect of aberrant expression on myogenesis [J]. J Neuroimmunol, 2002, 125(1-2) : 42-50.
  • 10Panieker JB, Chaeko G, Patil AK, et al. hnmunohistoehemieal differentiation of inflammato myopathies [ J ]. Neurol India, 2011 , 59(4) : 513-520.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部